受强制性开放获取政策约束的文章 - Robin Park, MD了解详情
可在其他位置公开访问的文章：5 篇
Cabozantinib plus durvalumab in advanced gastroesophageal cancer and other gastrointestinal malignancies: phase Ib CAMILLA trial results
A Saeed, R Park, J Dai, R Al-Rajabi, A Kasi, J Baranda, S Williamson, ...
Cell Reports Medicine 4 (2), 2023
强制性开放获取政策： US National Institutes of Health
Immunotherapy in Colorectal Cancer: Potential of Fecal Transplant and Microbiota-Augmented Clinical Trials
R Park, S Umar, A Kasi
Current Colorectal Cancer Reports, 2020
强制性开放获取政策： US National Institutes of Health
Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort
A Saeed, R Park, H Pathak, AN Al-Bzour, J Dai, M Phadnis, R Al-Rajabi, ...
Nature Communications 15 (1), 1533, 2024
强制性开放获取政策： US National Institutes of Health
Cyclosporine A Treatment Inhibits Abcc6-dependent Cardiac Necrosis and Calcification Following Coxsackievirus B3 Infection In Mice
J Marton, D Albert, SA Wiltshire, R Park, A Bergen, S Qureshi, D Malo, ...
PloS One 10 (9), 2015
强制性开放获取政策： Canadian Institutes of Health Research, Fonds de recherche du Québec - Santé
Phase I/II trial of cabozantinib plus durvalumab in advanced gastroesophageal cancer and other gastrointestinal malignancies (CAMILLA): phase Ib safety and efficacy results
A Saeed, R Park, J Dai, R Al-Rajabi, A Kasi, J Baranda, S Williamson, ...
强制性开放获取政策： US National Institutes of Health
出版信息和资助信息由计算机程序自动确定